Manufacturer Donations To Copay Charities: Profitability Underscores Kickback Concerns – Study
Department of Justice anti-kickback expert seeks to quantify the potential for manufacturers to benefit from donations to independent copay assistances organizations.
You may also be interested in...
In rare loss for FDA, appeals court reverses district court decision tossing Catalyst’s suit over Orphan Drug Act, saying deference should not have been granted to agency’s interpretation. District court finds it is too early to rule on one Pfizer charity co-pay program but backs broad reading of Anti-Kickback Statute.
Government claims Teva’s payments to two foundations to cover Copaxone copays violated Anti-Kickback statute. Teva is bucking settlement trend in DOJ’s industrywide investigation of sponsor ties to charitable foundations.
Packaging for such products reflects ‘unique circumstances’ that should exempt them from the rebates on discarded drugs otherwise required by the policy, stakeholders tell CMS at a ‘town hall’ forum.